Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Private Equity Firm Permira Seeks $4B Sale of CDMO Cambrex

Permira, a London-based private equity firm, is reportedly exploring the sale of contract development and manufacturing organization (CDMO) Cambrex in a deal that could value the company at up to $4 billion. The potential transaction underscores the growing investor interest in contract manufacturers, particularly amid the ongoing push for pharmaceutical manufacturing onshoring.

NoahAI News9/9/2025

Samsung Biologics Secures $1.3B Manufacturing Deal Amid Global Trade Tensions

South Korean contract development and manufacturing organization (CDMO) Samsung Biologics has inked a significant $1.3 billion manufacturing agreement with an undisclosed U.S. pharmaceutical company, highlighting the resilience of international partnerships in the face of ongoing trade uncertainties.

NoahAI News9/9/2025

Eli Lilly Unveils AI Platform to Accelerate Drug Discovery for Biotech Partners

Eli Lilly and Company has launched a groundbreaking artificial intelligence (AI) platform aimed at democratizing drug discovery for early-stage biotechnology companies. The initiative, named Lilly TuneLab, is part of the pharmaceutical giant's broader Catalyze360 program and represents a significant step towards collaborative innovation in the industry.

NoahAI News9/9/2025

Microbot Medical Receives FDA Clearance for Endovascular Robotic System, Poised to Enter U.S. Market

Microbot Medical has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Liberty Endovascular Robotic System, marking a significant milestone in the field of robotic-assisted peripheral vascular procedures. The clearance positions the company to begin marketing its innovative single-use, remotely operated robotic system in the United States.

NoahAI News9/9/2025

FDA's Advanced Manufacturing Technology Program Gains Momentum with New Designations

The U.S. Food and Drug Administration's (FDA) Advanced Manufacturing Technology (AMT) program is making significant strides in the pharmaceutical industry, with recent designations highlighting its potential to accelerate drug development and improve manufacturing processes. Ori Biotech and Cellares are among the latest companies to receive this coveted designation, joining a select group of innovators at the forefront of pharmaceutical manufacturing technology.

NoahAI News9/9/2025

Biogen's Lupus Pipeline Takes Center Stage, Highlighting Shift in Company Focus

Biogen, a pharmaceutical giant known for its multiple sclerosis (MS) treatments, is making significant strides in the lupus space, leveraging its immunological expertise to address an area of high unmet need. The company recently held an investor call showcasing its lupus portfolio, which includes two late-stage assets representing a multi-faceted approach to this complex autoimmune disease.

NoahAI News9/9/2025

BioNTech's Dual-Acting Lung Cancer Drug Shows Promise in Phase 2 Trial

BioNTech, in partnership with Bristol Myers Squibb, has announced encouraging results from a Phase 2 trial of their experimental bispecific cancer drug, pumitamig (BNT327). The drug, which targets both the PD-1 immune pathway and the cancer growth driver VEGF, demonstrated significant efficacy in treating small cell lung cancer (SCLC).

NoahAI News9/9/2025

New Class of Sleep Drugs Shows Promise in Narcolepsy Treatment

A new era in sleep medicine is dawning as multiple pharmaceutical companies present promising clinical trial data for drugs targeting the orexin-2 protein. These novel treatments, aimed at combating narcolepsy, have shown significant improvements in wakefulness and cataplexy control, potentially offering new hope for patients struggling with this chronic sleep disorder.

NoahAI News9/9/2025

Alkermes' Narcolepsy Drug Shows Promise in Phase II Trial, Outperforming Takeda's Competitor

Alkermes, the Dublin-based pharmaceutical company, has made significant strides in the treatment of narcolepsy type 1 with its drug alixorexton, presenting promising results from its Phase II Vibrance-1 trial at the World Sleep Congress 2025. The study demonstrated improvements in wakefulness, cognition, and fatigue over a six-week period, potentially positioning alixorexton as a strong competitor to Takeda's TAK-861 in the sleep disturbance space.

NoahAI News9/9/2025

Rapport Therapeutics' Seizure Drug Shows Promising Phase 2a Results, Sending Stock Soaring

Rapport Therapeutics, a neurology-focused biopharmaceutical company, has announced groundbreaking results from its Phase 2a trial of RAP-219, a novel drug candidate for treating drug-resistant focal onset seizures. The data, which exceeded analyst expectations, led to a dramatic surge in the company's stock price and has sparked optimism about a potential new treatment option for epilepsy patients.

NoahAI News9/9/2025

Summit's Ivonescimab Shows Mixed Results in Phase III NSCLC Trial, Raising Questions for FDA Approval

Summit Therapeutics' bispecific antibody ivonescimab has demonstrated varied efficacy across different patient populations in its Phase III HARMONi trial for non-small cell lung cancer (NSCLC), potentially complicating its path to FDA approval. The trial results, presented at the 2025 World Conference on Lung Cancer, reveal geographical inconsistencies in overall survival (OS) benefits, particularly between Asian and Western patient cohorts.

NoahAI News9/9/2025

Servier Invests $450M in Kaerus' Fragile X Syndrome Therapy, Expanding Neuroscience Portfolio

French pharmaceutical company Servier has announced a significant investment in Kaerus Bioscience's fragile X syndrome candidate, KER-0193, in a deal worth up to $450 million. This move marks Servier's latest effort to strengthen its neuroscience pipeline and expand its presence in the rare disease market.

NoahAI News9/9/2025

«1...64 65 66 67 »